New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:49 EDTBMYBristol-Myers sees 'encouraging' trends for Eliquis with hopes of expansion
Expects to have data from third line Phase II study in squamous non-small cell lung cancer in first part of 2014. It will also continue to explore combinations as well as initiating first line Phase III monotherapy study. Bristol-Myers said assets in the U.S. are in a much better position entering 2014 for both commercial and Medicare Part D plans. Total commercial costs in 2014 are expected to increase from 2013 due to the diabetes transaction. Comments taken from Q4 earnings conference call.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:52 EDTBMYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:33 EDTBMYBristol-Myers receives positive CHMP opinion for Nivolumab
Subscribe for More Information
May 21, 2015
07:37 EDTBMYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:01 EDTBMYBristol-Myers receives amended breakthrough therapy designation for daclatasvir
Subscribe for More Information
07:21 EDTBMYUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTBMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:56 EDTBMYGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 14, 2015
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMYAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:22 EDTBMYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTBMYBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use